Abstract
Primary adrenal lymphoma (PAL) is a rare extranodal non-Hodgkin’s lymphoma. The majority of the patients are elderly men with bilateral adrenal involvements. The optimal treatment of PAL has not been well established currently. We herein report on a patient with primary bilateral adrenal lymphoma and adrenal crisis that treated with rituximab. Our case does demonstrate that rituximab could be administered without significant toxicities, and resulted in clinical improvement with disease stabilization in this critically ill patient.
Similar content being viewed by others
References
Kumar R et al. FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 2005;30:222–30.
Fukushima A et al. Primary bilateral adrenal intravascular large B-cell lymphoma associated with adrenal failure. Intern Med 2003;42:609–14.
Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42.
Pfreundschuh M et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–91.
Mantzios G et al. Primary adrenal lymphoma presenting as Addison’s disease: case report and review of the literature. Ann Hematol 2004;83:460–63.
Shirao S et al. Effective combined modality therapy for a patient with primary adrenal lymphoma. Rinsho Ketsueki 2006;47:204–09.
Padate BP, Keidan J. Enteroviral meningoencephalitis in a patient with non-Hodgkin’s lymphoma treated previously with rituximab. Clin Lab Haematol 2006;28:69–71.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, KH., Chiou, TY., Lin, CJ. et al. Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis. Med Oncol 25, 107–109 (2008). https://doi.org/10.1007/s12032-007-0051-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-007-0051-7